GRAIL, Inc. Common Stock GRALV
Day range unavailable
52-week range unavailable
- Market cap
- 579.39M
- Revenue (ttm)
- 100.18M
- Shares out
- 31.10M
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 5.78
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 36.00%
- Free cash flow
- 0
- Total cash
- 199.72M
- Total debt
- 79.94M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 15.94
- 200-day average
- 15.94
Next earnings
Consensus EPS estimate 0.00.
About GRAIL, Inc. Common Stock
GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. GRAIL, LLC was formerly known as PSC15, Inc. and changed its name to GRAIL, LLC in January 2016. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, LLC operates as a subsidiary of Illumina, Inc.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- grail.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on GRALV — it syncs with the Stock Master app.